简 繁
Press Release
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Apr 15, 2026
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)

➞
Apr 15, 2026
Global First | NMPA Accepts IND Application for Mabwell’s Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311

➞
Apr 14, 2026
SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial.

➞
Mar 25, 2026
Mabwell Established a Licensing and Commercialization Agreement of Denosumab Biosimilars for Vietnamese Market

➞
Mar 12, 2026
Dr. Liu Datao Attends "Focus on the Two Sessions · 2026 6th Ophthalmology Summit"

➞
Feb 05, 2026
Mabwell Announces Strategic Partnership with MediTrust Health

➞
Jan 26, 2026
Cell Reports | Mabwell collaborates with SIOC, CAS and SJTU to publish research results on a monoclonal antibody targeting α-synuclein fibrils, revealing its potential to halt Parkinson’s disease progression

➞
Jan 21, 2026
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.

➞
Jan 06, 2026
SynuSight Biotech, an Incubated Company of Mabwell, and ABLi Therapeutics Enter into a License Agreement for [18F]-FD4 to Advance Clinical Research for Parkinson’s Disease

➞
Previous1 2